Correlation Between Gap, and Eupraxia Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Gap, and Eupraxia Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Gap, and Eupraxia Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between The Gap, and Eupraxia Pharmaceuticals Common, you can compare the effects of market volatilities on Gap, and Eupraxia Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Gap, with a short position of Eupraxia Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Gap, and Eupraxia Pharmaceuticals.

Diversification Opportunities for Gap, and Eupraxia Pharmaceuticals

-0.65
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Gap, and Eupraxia is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding The Gap, and Eupraxia Pharmaceuticals Commo in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eupraxia Pharmaceuticals and Gap, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on The Gap, are associated (or correlated) with Eupraxia Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eupraxia Pharmaceuticals has no effect on the direction of Gap, i.e., Gap, and Eupraxia Pharmaceuticals go up and down completely randomly.

Pair Corralation between Gap, and Eupraxia Pharmaceuticals

Considering the 90-day investment horizon The Gap, is expected to under-perform the Eupraxia Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, The Gap, is 1.06 times less risky than Eupraxia Pharmaceuticals. The stock trades about -0.08 of its potential returns per unit of risk. The Eupraxia Pharmaceuticals Common is currently generating about 0.15 of returns per unit of risk over similar time horizon. If you would invest  300.00  in Eupraxia Pharmaceuticals Common on December 19, 2024 and sell it today you would earn a total of  102.00  from holding Eupraxia Pharmaceuticals Common or generate 34.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

The Gap,  vs.  Eupraxia Pharmaceuticals Commo

 Performance 
       Timeline  
Gap, 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days The Gap, has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Eupraxia Pharmaceuticals 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals Common are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Eupraxia Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Gap, and Eupraxia Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Gap, and Eupraxia Pharmaceuticals

The main advantage of trading using opposite Gap, and Eupraxia Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Gap, position performs unexpectedly, Eupraxia Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will offset losses from the drop in Eupraxia Pharmaceuticals' long position.
The idea behind The Gap, and Eupraxia Pharmaceuticals Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format